Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Claim this profile,
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Lymphoma
Conducts research for Leukemia
198 reported clinical trials
30 medical researchers
Summary
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Tumors, Recurrence, Lymphoma, Leukemia and other specialties. Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center is involved with conducting 198 clinical trials across 431 conditions. There are 30 research doctors associated with this hospital, such as Julie Kim, Angela Ricci, Kathryn C. Hourdequin, and Konstantin H. Dragnev.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Julie KimDartmouth Hitchcock Medical Center6 years of reported clinical research
Expert in Tumors
Studies Leukemia
26 reported clinical trials
72 drugs studied
Angela RicciDartmouth Hitchcock Medical Center/Dartmouth Cancer Center6 years of reported clinical research
Studies Tumors
Studies Lymphoma
20 reported clinical trials
63 drugs studied
Kathryn C. HourdequinDartmouth Hitchcock Medical Center/Dartmouth Cancer Center4 years of reported clinical research
Studies Cancer
Studies Adenocarcinoma
18 reported clinical trials
34 drugs studied
Konstantin H. DragnevDartmouth Hitchcock Medical Center5 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
41 drugs studied
Clinical Trials running at Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Breast Cancer
Prostate Cancer
Cancer
Pancreatic Cancer
Brain Tumor
Bladder Cancer
Lung Cancer
Lymphoma
Rectal Cancer
Squamous Cell Carcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This study is evaluating whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center?
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Tumors, Recurrence, Lymphoma, Leukemia and other specialties. Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center is involved with conducting 198 clinical trials across 431 conditions. There are 30 research doctors associated with this hospital, such as Julie Kim, Angela Ricci, Kathryn C. Hourdequin, and Konstantin H. Dragnev.